Epibiotech

Epi Biotech, based in South Korea, focuses on developing innovative biopharmaceuticals to treat hair loss by utilizing advanced cellular and genetic therapies. Epi Biotech Co. , Ltd. was founded in 2015 in Incheon, South Korea.

The company specializes in developing biopharmaceuticals for hair loss treatment. Epi Biotech Co. , Ltd. was founded in 2015 in Incheon, South Korea.

The company specializes in developing biopharmaceuticals for hair loss treatment. In December 2022, Epibiotech raised KRW 1. 5 billion in venture funding from Daewoong Pharmaceutical, valuing the company at KRW 67. 36 billion post-money.

Epi Biotech specializes in the development of advanced biopharmaceuticals aimed at addressing unmet medical needs in hair loss treatment. The company's core product offerings include cellular, genetic, and antibody-based therapies designed to stimulate hair regrowth and improve hair follicle health. These products are part of a comprehensive solution targeting various forms of alopecia, leveraging technologies such as stem cell and gene therapy. Epi Biotech serves a diverse client base including research institutions, biotech firms, and healthcare providers, particularly in Asian markets like South Korea and China, and has engaged in collaborative research initiatives, such as a recent symposium with Yonsei University's Comprehensive Pharmaceutical Research Institute.

Epi Biotech's revenue model is structured around collaborations and partnerships with research institutions and healthcare organizations, facilitating the distribution of its biopharmaceutical products. The company engages in business-to-business (B2B) transactions, providing its therapies directly to academic and medical entities. Revenue generation is supported through contractual agreements for research, development, and clinical trials of proprietary products, with pricing structures tailored to client needs, ensuring competitive positioning in the biotech sector. Epi Biotech plans to launch new products aimed at enhancing hair loss treatment, with specific release dates yet to be announced.

The company is targeting expansion into the Chinese market by 2024 to broaden its geographic reach. The December 2022 funding will be utilized to support these initiatives and enhance their research and development efforts. Additionally, in July 2023, Epi Biotech was listed on the KONEX stock exchange, marking a significant milestone for the company.